MedTrace Logo

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

NCT02541084 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2017-08-22

No results posted yet for this study

Summary

This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.

Conditions

  • Wet Macular Degeneration

Interventions

DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Anti-VEGF therapy following the Summary of Product Characteristics

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-18
Primary Completion
2016-03-30
Completion
2016-07-30

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02541084 on ClinicalTrials.gov